1. Zaynich US launch - Zaynich (WCK 5222) received US FDA approval on 30 May 2026 for cUTI, with a label covering Enterobacterales and Pseudomonas and breakpoints covering \~95% of carbapenem-resistant cases in the US. The US gram-negative hospital infection market is \~1.2 million cases annually, and management targets 20-25% market share of resistant cases, with the US typically representing \~40% of global revenue for anti-infectives.
2. Zaynich India launch - Zaynich was approved by the DCGI on 27 May 2026, and the company will market it directly through a multi-channel specialist force targeting intensivists and disease specialists within the first 6-9 months. Management is targeting 20,000-30,000 patients in the first phase, translating to ₹200-400 crore in sales, and 80,000-100,000 patients within 3 years, against an addressable market of \~₹17,000 crore.
3. Zaynich EMA approval - A Marketing Authorisation Application was submitted to the EMA on 5 January 2026 covering 30 countries, and the agency granted Accelerated Assessment. Approval was expected by end of 2026, opening a market that together with the US represents a $7 billion addressable opportunity across 371,000 cases.
4. Novo Nordisk insulin gap - Novo Nordisk’s decision to discontinue disposable insulin pens and cartridges opens a space worth \~₹450 crore in India and $157 million in emerging markets. Wockhardt, already the fastest-growing among the top 5 insulin companies in India with in-house pen platforms, is positioned to capture this demand as it scales capacity.
5. Balance sheet capacity for growth - Net debt-to-equity stood at 0.10 as of March 2026, with cash of ₹662 crore and ICRA rating upgraded to A- (Stable)/A2+ in May 2026. The strengthened balance sheet funds the ongoing ₹200-300 crore annual capex for biologics capacity and the Zaynich commercial build-out without requiring fresh dilution.
6. Emrok franchise extension - Emrok and Emrok O have treated over 100,000 patients and captured \~10% market share in the anti-MRSA segment, with FY26 growth of \~50%. The company is now expanding into new indications and specialties in India, while registration has been filed in 9-10 international markets.
7. UK and Ireland generics stability - The UK business grew 13% in FY26 and contributes 39% of total revenue, with an 18% market share in the covered market, while Ireland grew 16% and contributes 11%. These businesses provide a steady base of specialty injectables and liquids/creams revenue that funds R&D while the novel antibiotic portfolio commercialises.